Vifor Pharma AG (LTS:0RPD) 3-Year Revenue Growth Rate : 7.40% (As of Dec. 2021)

View and export this data going back to 2014. Start your Free Trial

What is Vifor Pharma AG 3-Year Revenue Growth Rate?

Vifor Pharma AG's Revenue per Share for the six months ended in Dec. 2021 was CHF14.87.

During the past 12 months, Vifor Pharma AG's average Revenue per Share Growth Rate was -2.30% per year. During the past 3 years, the average Revenue per Share Growth Rate was 7.40% per year. During the past 5 years, the average Revenue per Share Growth Rate was 12.50% per year. During the past 10 years, the average Revenue per Share Growth Rate was -8.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 13 years, the highest 3-Year average Revenue per Share Growth Rate of Vifor Pharma AG was 19.80% per year. The lowest was -32.70% per year. And the median was 7.50% per year.

Competitive Comparison of Vifor Pharma AG's 3-Year Revenue Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Vifor Pharma AG's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vifor Pharma AG's 3-Year Revenue Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Vifor Pharma AG's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Vifor Pharma AG's 3-Year Revenue Growth Rate falls into.

Vifor Pharma AG 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Vifor Pharma AG (LTS:0RPD) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

Vifor Pharma AG 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Vifor Pharma AG's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Vifor Pharma AG (LTS:0RPD) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Vifor Pharma AG (LTS:0RPD) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

Rechenstrasse 37, Saint Gallen, CHE, 9014

Website

https://www.viforpharma.com

Vifor Pharma AG is a specialty drug manufacturing and licensing company. It researches, develops, and produces its pharmaceutical products and markets and distributes them worldwide. Most of its sales are generated in the USA, with Europe also a strong contributor. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Vifor Pharma AG (LTS:0RPD) Headlines

No Headlines